转移性晚期-话题@MedSci

#转移性晚期#

3篇内容 | 315人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1813674, encodeId=68c418136e43b, content=<a href='/topic/show?id=0dca9341636' target=_blank style='color:#2F92EE;'>#转移性晚期#</a>, objectTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, objectType=article, longId=738547, objectId=dd49e385472d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd49e385472d, replyNumber=0, likeNumber=37, createdTime=2023-08-19, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd49e385472d, moduleTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd49e385472d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813673, encodeId=533918136e3d3, content=<a href='/topic/show?id=0dca9341636' target=_blank style='color:#2F92EE;'>#转移性晚期#</a>, objectTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, objectType=article, longId=176830, objectId=36111e683054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36111e683054, replyNumber=0, likeNumber=43, createdTime=2019-12-20, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36111e683054, moduleTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36111e683054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813672, encodeId=953018136e2b8, content=<a href='/topic/show?id=0dca9341636' target=_blank style='color:#2F92EE;'>#转移性晚期#</a>, objectTitle=无法手术的晚期肺癌患者生存结果大不同——局部晚期&转移性晚期肺癌, objectType=article, longId=167387, objectId=5acb16e38737, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5acb16e38737, replyNumber=0, likeNumber=48, createdTime=2020-03-18, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5acb16e38737, moduleTitle=无法手术的晚期肺癌患者生存结果大不同——局部晚期&转移性晚期肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5acb16e38737)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性晚期

2020-05-29

41514487@qq.com (审核中...)

前往app查看评论内容

#转移性晚期#

JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌

2023-08-19

41514487@qq.com (审核中...)

前往app查看评论内容

#转移性晚期#

不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验

2019-12-20

41514487@qq.com (审核中...)

前往app查看评论内容

#转移性晚期#

无法手术的晚期肺癌患者生存结果大不同——局部晚期&转移性晚期肺癌

2020-03-18

科室
- - 订阅+
  - 更多科室
工具
服务